How will Aducanumab approval impact Alzheimer’s disease research?

Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust William, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Mindt MR, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Journal of Prevention of Alzheimer's Disease July 2021  

Should you find out if you’re at risk of Alzheimer’s?

The Wall Street Journal |
July 2019

Dr. Robert Green on learning of your genetic risk to developing Alzheimer’s quotes:  “Not everything has a pill or medical-prevention plan, but many information-seeking persons can find all sorts of benefits in better understanding their risk of future disease.”

Diagnosis and Management of Alzheimer’s Disease and Other Dementias


Robert C. Green
January 2005  

Plenary presentation at the Advances in Genome Biology and Technology Precision Health Meeting

AGBT Precision Health Conference |
September 2018

Dr. Robert C. Green speaks at the 2018 Advances in Genome Biology and Technology (AGBT) Precision Health Conference in San Diego, California about our efforts to gather empirical data on genome sequencing healthy individuals. Watch to learn more about G2P’s MilSeq, BabySeq, MedSeq, PeopleSeq, PGen and REVEAL projects. Click here for more on the conference.

G2P Newsletter May 2017

Genomes2People |
May 2017
G2P News

In spring, The New York Times highlighted G2P’s work with REVEAL-SCAN, team members participated in a 10k marathon to raise money for genetic research, and G2P researchers published a new article on direct-to-consumer testing.

New gene tests pose a threat to insurers

New York Times |
May 2017

Dr. Green has found that people who learn they have the ApoE4 gene fare just as well if they get the results without counseling.those who learned they had the gene variant — Ms. Reilly was one of them — were nearly six times more likely to buy long-term care insurance than those who did not.

Crowdsourced estimation of cognitive decline and resilience in Alzheimer’s disease

Allen GI, Amoroso N, Anghel C, Balagurusamy V, Bare CJ, Beaton D, Bellotti R, Bennett DA, Boehme K, Boutros PC, Caberlotto L, Caloian C, Campbell F, Neto EC, Chang Y-C, Chen B, Chen C-Y, Chien T-Y, Clark T, Das S, Davatzikos C, Deng J, Dillenberger D, Dobson RJB, Don Q, Doshi J, Duma D, Errico R, Erus G, Everett E, Fardo DW, Friend SH, Fröhlich H, Gan J, St. George-Hyslop P, Ghosh SS, Glaab E, Green RC, Guan Y, Hong M-Y, Huang C, Hwang J, Ibrahim J, Inglese P, Jiang Q, Katsumata Y, Kauwe JSK et al.
Alzheimer's & Dementia May 2016  

Genomes2People: a roadmap for genomic medicine

Front Line Genomics |
May 2016

An overview and summary of the main projects that are being conducted within the G2P program, both past and present. This article also includes the progract managers and research assistants on each major project.

Global and local ancestry in African Americans: Implications for Alzheimer’s disease risk

Hohman TJ, Cooke-Bailey JN, Reitz C, Jun G, Naj A, Beecham GW, Liu Z, Carney RM, Vance JM, Cuccaro ML, Rajbhandary R, Vardarajan BN, Wang L-S, Valladares O, Lin C-F, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue MW, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RCP, Griffith P, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hardy J, Hendrie HC, Hall KS, Goate AM, Lang R, Byrd GS, Kukull WA, Foroud TM, Farrer LA, Martin ER, Pericak-Vance MA, Schellenberg GD, Mayeux R, Haines JL, Thornton-Wells TA
Alzheimer's & Dementia March 2016  

More information on genetic risks is actually reassuring, study finds

Boston Globe |
February 2016

Within the REVEAL-SCAN study, one group of participants are given back the results on Alzheimer’s and additional heart disease information. Patients who are receiving the additional information are finding it reassuring that they can take measures to prevent at least one of their possible conditions if they have mutations for both.

No worries! CAD risk disclosure OK at Alzheimer’s genotyping

Medscape |
January 2016

Through the REVEAL study, researchers were testing to see how participants anxiety, depression, and test-related distress would be affected by knowing their genetic results of Alzheimer’s Disease and Coronary artery disease.

Disclosure of incidental genetic findings can have positive impact for patients

Brigham Women's Hospital |
January 2016
Press Release

A new study has found that providing unanticipated information about risk of coronary artery disease during a genetic risk assessment for Alzheimer’s disease helped some participants cope with their results, and also motivated participants to make changes to their health behaviors. The results of the randomized controlled study are published online in the journal Annals of … Continued

Latest News From Genomes2People